Business & Finance
Hansa Medical widens loss in Q3 2018
2 November 2018 -

Hansa Medical AB (STO:HMED) on Thursday reported net loss of SEK61,451,000, or SEK1.61 per diluted share, for the third quarter of 2018, from July 2018 to September 2018.

This was a decline over net loss of SEK37,527,000, or SEK1.06 per diluted share, in Q3 2017.

Net revenues for the quarter were SEK484,000, as compared with SEK678,000 in Q3 2017.

The company added that the development of its lead candidate imlifidase, formerly known as IdeS, continues to progress according to plan. To date, the company has successfully designed and managed a series of clinical studies, demonstrating its ability to enable life-saving kidney transplantation in highly sensitised patients, an indication where there is significant unmet medical need.

Also, at the end of the quarter, the company announced the successful completion of two phase 2 clinical studies of imlifidase for kidney transplantation in highly sensitised patients, in which imlifidase enabled transplantation in all 35 evaluated patients.